Joshua Reed

Joshua Reed joined Omega Therapeutics as Chief Financial Officer in and brings extensive experience successfully executing diverse corporate and financial operations. Prior to Omega, Mr. Reed most recently served as Chief Financial Officer of Aldeyra Therapeutics, where he was responsible for finance, business development, investor relations, compliance, human resources, and information technology. During his time at Aldeyra, Mr. Reed led multiple capital raises, oversaw the company’s interactions with current and prospective investors and managed all aspects of the company’s financial processes, including quarterly and annual SEC filings.

Previously, Mr. Reed held a variety of finance roles of increasing responsibility at Bristol-Myers Squibb, most recently serving as Vice President and Head of Finance Operations for the United States and Puerto Rico. While at Bristol-Myers Squibb, Mr. Reed also led financial planning and analysis, supply chain, and manufacturing finance, and worked on various acquisitions, divestitures, alliances and collaboration agreements. Prior to joining the bio-pharmaceutical industry, Mr. Reed was the Vice President, Strategic Business Development at JPMorgan Chase, and held investment banking positions at Credit Suisse First Boston, where he focused on mergers and acquisitions. Mr. Reed began his career at JPMorgan Chase, Credit Suisse First Boston, and Chase Manhattan Bank. Mr. Reed currently serves on the Board of Directors and as Chairman of the Audit Committee of Scholar Rock, a publicly traded biotechnology company.

Mr. Reed received his B.S. in Finance from Rutgers University and his MBA from the University of Michigan’s Ross School of Business.